• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    5/13/24 12:38:48 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVTX alert in real time by email
    SC 13G 1 avalo13g-05132024.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C.  20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.  )*

    Avalo Therapeutics, Inc.
    (Name of Issuer)

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

    05338F306
    (CUSIP Number)

    May 1, 2024
    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]             Rule 13d-1(b)
    [x]             Rule 13d-1(c)
    [ ]             Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    1.
    NAMES OF REPORTING PERSONS
     
     
     
    Allostery Master Fund LP
     
     
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     
     
     
    (a) [ ]
     
    (b) [ ]
     
     
    3.
    SEC USE ONLY
     
     
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Cayman Islands
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
     
     
    5.
    SOLE VOTING POWER
     
     
     
    0
     
     
    6.
    SHARED VOTING POWER
     
     
     
    78,255
     
     
    7.
    SOLE DISPOSITIVE POWER
     
     
     
    0
     
     
    8.
    SHARED DISPOSITIVE POWER
     
     
     
    78,255
     
     
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    78,255
     
     
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
     
     
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
    7.6%
     
     
    12.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    PN
     
     




    1.
    NAMES OF REPORTING PERSONS
     
     
     
    Allostery Investments LP
     
     
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     
     
     
    (a) [ ]
     
    (b) [ ]
     
     
    3.
    SEC USE ONLY
     
     
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Delaware
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
     
     
    5.
    SOLE VOTING POWER
     
     
     
    0
     
     
    6.
    SHARED VOTING POWER
     
     
     
    78,255
     
     
    7.
    SOLE DISPOSITIVE POWER
     
     
     
    0
     
     
    8.
    SHARED DISPOSITIVE POWER
     
     
     
    78,255
     
     
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    78,255
     
     
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
     
     
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
    7.6%
     
     
    12.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    PN
     
     




    NAMES OF REPORTING PERSONS
     
    Allostery Investments GP LLC
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     
    (a) [ ]
    (b) [ ]
     
    SEC USE ONLY
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
     
    SOLE VOTING POWER
     
    0
     
    SHARED VOTING POWER
     
    78,255
     
    SOLE DISPOSITIVE POWER
     
    0
     
    SHARED DISPOSITIVE POWER
     
    78,255
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    78,255
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    7.6%
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    OO
     
     


    1.
    NAMES OF REPORTING PERSONS
     
     
     
    Christopher Staral
     
     
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     
     
     
    (a) [ ]
     
    (b) [ ]
     
     
    3.
    SEC USE ONLY
     
     
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    United States
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
     
     
    5.
    SOLE VOTING POWER
     
     
     
    0
     
     
    6.
    SHARED VOTING POWER
     
     
     
    78,255
     
     
    7.
    SOLE DISPOSITIVE POWER
     
     
     
    0
     
     
    8.
    SHARED DISPOSITIVE POWER
     
     
     
    78,255
     
     
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    78,255
     
     
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
     
     
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
    7.6%
     
     
    12.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    IN
     
     



    1.
    NAMES OF REPORTING PERSONS
     
     
     
    David Modest
     
     
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     
     
     
    (a) [ ]
     
    (b) [ ]
     
     
    3.
    SEC USE ONLY
     
     
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    United States
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
     
     
    5.
    SOLE VOTING POWER
     
     
     
    0
     
     
    6.
    SHARED VOTING POWER
     
     
     
    78,255
     
     
    7.
    SOLE DISPOSITIVE POWER
     
     
     
    0
     
     
    8.
    SHARED DISPOSITIVE POWER
     
     
     
    78,255
     
     
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    78,255
     
     
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
     
     
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
    7.6%
     
     
    12.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    IN
     
     

    Item 1(a).
    Name of Issuer:

    Avalo Therapeutics, Inc. (“Issuer”)

    Item 1(b).
    Address of Issuer’s Principal Executive Offices:

    540 Gaither Road, Suite 400, Rockville, MD 20850

    Item 2(a).
    Name of Persons Filing:

    The names of the persons filing this statement on Schedule 13G are (collectively, the “Reporting Persons”):


    •
    Allostery Master Fund LP, a Cayman Islands exempted limited partnership (“Allostery Master Fund”);


    •
    Allostery Investments LP, a Delaware limited partnership (“Allostery Investments”);


    •
    Allostery Investments GP LLC, a Delaware limited liability company (“Allostery Investments GP”);


    •
    Christopher Staral, a United States citizen (“Mr. Staral”); and


    •
    David Modest, a United States citizen (“Mr. Modest”).

    Item 2(b).
    Address of Principal Business Office or, if None, Residence:

    The principal business address of each of the Reporting Persons is One Stamford Plaza, 9th Floor, 263 Tresser Boulevard, Stamford, CT 06901.

    Item 2(c).
    Citizenship:

    Allostery Master Fund LP is a Cayman Islands exempted limited partnership. Allostery Investments LP is a Delaware limited partnership. Allostery Investments GP LLC is a Delaware limited liability company. Messrs. Staral and Modest are citizens of the United States.

    Item 2(d).
    Title of Class of Securities:

    Common Stock, par value $0.001 per share (the “Common Stock”)

    Item 2(e).
    CUSIP Number:

    05338F306

    Item 3.
    If This Statement is Filed Pursuant to Rule 13d 1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Exchange Act.
     
     
     
     
     
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Exchange Act.
     
     
     
     
     
    (c)
    [ ]
    Insurance company defined in Section 3(a)(19) of the Exchange Act.
     
     
     
     
     
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act.
     
     
     
     
     
    (e)
    [ ]
    Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
     
     
     
     
     
    (f)
    [ ]
    Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).




     
     
     
     
     
    (g)
    [ ]
    Parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
     
     
     
     
     
    (h)
    [ ]
    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
     
     
     
     
     
    (i)
    [ ]
    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
     
     
     
     
     
    (j)
    [ ]
    Non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J).
     
     
     
     
     
    (k)
    [ ]
    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

    Item 4.
    Ownership.

    (a)
    Amount beneficially owned:

    As of May 1, 2024, Allostery Master Fund beneficially owned 78,255 shares of Common Stock.

    Allostery Investments, as the investment manager of Allostery Master Fund, may be deemed to have beneficially owned the 78,255 shares of Common Stock beneficially owned by Allostery Master Fund.

    Allostery Investments GP, as the general partner of Allostery Investments, may be deemed to have beneficially owned the 78,255 shares of Common Stock beneficially owned by Allostery Investments.

    Messrs. Modest and Staral, as the managing members of Allostery Investments GP,  may be deemed to have beneficially owned the 78,255 shares of Common Stock beneficially owned by Allostery Investment GP.

    (b)
    Percent of Class:

    The following percentage is based on 1,034,130 shares of Common Stock outstanding as of March 27, 2024, as disclosed in the Issuer’s Current Report on Form 10-K filed with the Securities and Exchange Commission on March 29, 2024.

    As of May 1, 2024, the Reporting Persons may be deemed to have beneficially owned approximately 7.6% of the outstanding Common Stock.

    (c)
    Number of shares as to which such person has:

    (i)
    Sole power to vote or to direct the vote:

    See Cover Pages Items 5-8.

    (ii)
    Shared power to vote or to direct the vote:

    See Cover Pages Items 5-8.

    (iii)
    Sole power to dispose or to direct the disposition:

    See Cover Pages Items 5-8.

    (iv)
    Shared power to dispose or to direct the disposition:

    See Cover Pages Items 5-8.



    Item 5.
    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

    Item 8.
    Identification and Classification of Members of the Group.

    See Exhibit A.

    Item 9.
    Notice of Dissolution of Group.

    Not applicable.

    Item 10.
    Certification.

    By signing below each of the undersigned certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURES
    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

    Dated: May 13, 2024

    ALLOSTERY MASTER FUND LP
    By: Allostery Investments LP, its investment manager
    By: Allostery Investments GP LLC, its general partner
     
    By:
    /s/ David Modest
     
     
    David Modest, Managing Member
     
     
     

    ALLOSTERY INVESTMENTS LP
    By: Allostery Investments GP LLC, its general partner
     
    By:
    /s/ David Modest
     
     
    David Modest, Managing Member

    ALLOSTERY INVESTMENTS GP LLC
     
    By:
    /s/ David Modest
     
     
    David Modest, Managing Member

    /s/ Christopher Staral
       
    CHRISTOPHER STARAL
     

    /s/ David Modest
       
    DAVID MODEST
     



    EXHIBIT A
    JOINT FILING AGREEMENT
    The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Avalo Therapeutics, Inc. dated as of May 13, 2024, is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(2) under the Securities Exchange Act of 1934, as amended.
    Dated: May 13, 2024

    ALLOSTERY MASTER FUND LP
    By: Allostery Investments LP, its investment manager
    By: Allostery Investments GP LLC, its general partner
     
    By:
    /s/ David Modest
     
     
    David Modest, Managing Member
     
     
     

    ALLOSTERY INVESTMENTS LP
    By: Allostery Investments GP LLC, its general partner
     
    By:
    /s/ David Modest
     
     
    David Modest, Managing Member

    ALLOSTERY INVESTMENTS GP LLC
     
    By:
    /s/ David Modest
     
     
    David Modest, Managing Member

    /s/ Christopher Staral
       
    CHRISTOPHER STARAL
     

    /s/ David Modest
       
    DAVID MODEST
     


    Get the next $AVTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVTX

    DatePrice TargetRatingAnalyst
    3/25/2025$36.00Buy
    Stifel
    3/25/2025$23.00Buy
    Jefferies
    2/28/2025$48.00Overweight
    Piper Sandler
    2/21/2025$18.00Outperform
    Wedbush
    12/19/2024$40.00Buy
    BTIG Research
    10/24/2024Neutral
    H.C. Wainwright
    4/16/2024$35.00Perform → Outperform
    Oppenheimer
    3/3/2022$5.00 → $0.75Buy → Hold
    Jefferies
    More analyst ratings

    $AVTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

      WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 3:00 pm ET. Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days. About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company

      4/30/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Reports 2024 Financial Results and Recent Business Updates

      Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024. "2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time," said Dr. Garry Neil,

      3/20/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Reports 2024 Financial Results and Recent Business Updates

      Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024. "2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time," said Dr. Garry Neil,

      3/20/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

      WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In this newly created role, Ms. Riley will oversee corporate strategy and commercial and product pipeline planning, with a goal of driving growth and innovation across the organization. "We are thrilled to welcome Jennifer to Avalo in the newly established role of Chief Strategy Officer," said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. "Jennifer brings extensive leadership

      1/2/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Avalo Therapeutics Inc.

      SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

      11/14/24 6:23:00 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avalo Therapeutics Inc.

      SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

      11/14/24 12:05:55 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avalo Therapeutics Inc.

      SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

      11/7/24 5:00:07 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chan Mitchell converted options into 3,167 shares (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      4/1/25 8:06:11 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Goldman Jonathan converted options into 3,167 shares (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      4/1/25 4:55:44 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Truex Samantha converted options into 3,167 shares (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      4/1/25 4:44:14 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Almenoff June Sherie bought $12,750 worth of shares (1,000 units at $12.75) (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      11/14/24 5:21:55 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel initiated coverage on Avalo Therapeutics with a new price target

      Stifel initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $36.00

      3/25/25 8:26:24 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Avalo Therapeutics with a new price target

      Jefferies initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $23.00

      3/25/25 8:26:24 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Avalo Therapeutics with a new price target

      Piper Sandler initiated coverage of Avalo Therapeutics with a rating of Overweight and set a new price target of $48.00

      2/28/25 7:19:02 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    SEC Filings

    See more
    • Avalo Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      5/8/25 7:02:47 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Avalo Therapeutics Inc.

      DEFA14A - Avalo Therapeutics, Inc. (0001534120) (Filer)

      5/1/25 7:02:41 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Avalo Therapeutics Inc.

      DEF 14A - Avalo Therapeutics, Inc. (0001534120) (Filer)

      5/1/25 7:00:42 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care